Evogene (TSE:EVGN – Free Report) had its price objective lowered by Pi Financial from C$5.00 to C$4.00 in a research report sent to investors on Wednesday morning, BayStreet.CA reports.
Evogene Price Performance
About Evogene
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
See Also
- Five stocks we like better than Evogene
- Insider Selling Explained: Can it Inform Your Investing Choices?
- High-Yield Texas Instruments Could Hit New Highs Soon
- Most Volatile Stocks, What Investors Need to Know
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- The How And Why of Investing in Oil Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
